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The risk of ovarian epithelial neoplasia following use of hormonal contraceptives (HC) was examined in data from the Norwegian–
Swedish Women’s Lifestyle and Health cohort including 103551 women aged 30–49 years in 1991–92. Follow-up through 2000
produced 214 incident cases of histologically confirmed epithelial ovarian neoplasias (135 invasive and 79 borderline cases). Using the
Cox proportional hazard models, ever having used HC was associated with a decreased relative risk of epithelial ovarian cancer of 0.6
(95% CI 0.5–0.8). The effect of duration of HC use was convincing (P for trend o0.0001), and more important than age at start of
use or time since first or last use. There was no significant difference between the effects of combined oral contraceptives and
progestins-only contraceptives on risk (P¼0.98). Similarly, there was no significant difference between the effects of ever use of HC
on invasive and borderline ovarian neoplasia (P¼0.37). In this cohort, use of HC seems to reduce the risk of epithelial ovarian
neoplasia markedly and persistently in relation to the duration of use.
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That use of hormonal contraceptives (HC) may reduce the
incidence of ovarian cancer is well established from both case–
control (Weiss et al, 1981; Centers for Disease Control Cancer and
Steroid Hormone Study, 1987; The WHO Collaborative Study of
Neoplasia and Steroid Contraceptives, 1989; Franceschi et al, 1991;
Whittemore et al, 1992; Siskind et al, 2000) and cohort studies
(Ramcharan et al, 1980; Willett et al, 1981; Vessey et al, 1987; Beral
et al, 1988, 1999; Hankinson et al, 1995; Vessey and Painter, 1995),
as recently reviewed (IARC Working Group, 1999; La Vecchia and
Franceschi, 1999). Indeed, this benefit may be strong enough to
reduce population-based incidence rates in places where HC have
been used extensively (Adami et al, 1990; Parazzini et al, 2000;
Walker et al, 2002). Nevertheless, few studies have distinguished
between the two subtypes of epithelial ovarian neoplasias (EON):
invasive epithelial ovarian neoplasia (IEON) and borderline
epithelial ovarian neoplasia (BEON). Little is known about the
possible benefit of continued HC use for 10 or more years, and it is
unclear for how long the effect lasts following cessation of
treatment. A detailed understanding of the potential benefits of
using HC may be of considerable importance both for individual
women and for the public health. We present here results from a
large, population-based, prospective study: the Norwegian–
Swedish Women’s Lifestyle and Health cohort – with detailed
assessment of HC use and complete follow-up.
MATERIAL AND METHODS
Study cohort
In 1991–92, the Norwegian–Swedish Women’s Lifestyle and
Health cohort was established in Norway and Sweden. Using the
unique person number, 196000 women aged 30–49 years were
sampled at random among all women in their age group from the
Central Population Register in Norway and the Swedish Central
Population Registry at Statistics Sweden (Lunde et al, 1980). In
Norway, women aged 34–49 years (born 1943–57) at the time of
invitation were selected from the entire country. The Swedish
women were aged 30–49 years (born 1943–60) and residing in
Uppsala Health Care Region. The study population is described
elsewhere (Kumle et al, 2002). The 106841 women who responded
to the four-page self-instructed questionnaire were included in the
cohort, giving a response rate of 54.5%. The questionnaire
contained a set of identical questions in the two countries,
including detailed assessment of contraceptive use and reproduc-
tive history together with other lifestyle habits. To facilitate recall,
a colour brochure with pictures of almost all contraceptive pill
packages ever sold in Norway and Sweden was included with the
letter of invitation and questionnaire.
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vital status information (alive, dead or emigrated), 15 who were
dead or had emigrated before the start of follow-up and 1681
women who reported having an invasive cancer of any type at
study enrolment (information obtained from the cancer registries).
In addition, 1126 women who with lacked information on use of
HC and 463 who had undergone bilateral oophorectomy, and
therefore not at risk for ovarian cancer, were excluded from the
present analysis, leaving 103551 women eligible for follow-up.
Follow-up
We achieved complete follow-up through linkages between the
cohort data set and various population-based registries using the
individual unique national registration numbers (Lunde et al,
1980) assigned to all residents in Norway and Sweden. The
national cancer registers, established in the 1950s in both
countries, provided data on prevalent cancer cases at cohort
enrolment and incident cancers diagnosed in the cohort during the
follow-up. These cancer registries are estimated to be almost 100%
complete (Lund, 1981; Mattsson and Wallgren, 1984), and include
information on pathological tumour features.
The start of follow-up was defined as the date of return of the
questionnaire. We obtained information on the dates of death for
deceased persons from the death registers, and on the date of
emigration from the registers of population migration. The follow-
up ended on 31 December 2000, at emigration, death or diagnosis
of histologically confirmed primary EON, whichever occurred first.
Among the 106841 women enrolled initially into the cohort, 789
emigrated and 1360 died during the period of follow-up.
Exposure classification
The information about exposure to HC presented here is based on
answers to questions on summary measures as ever having used,
current use, total duration of use, age at first use, and use before
first full-term pregnancy. We also collected information about
each specific period of use. A period was defined as use of a
specified HC brand for at least 1 month. Up to 10 different periods
of use were reported. For each period, we asked for the age at
starting use, duration of use and brand name. We calculated the
time since last use as the interval between the end of use and start
of the follow-up. ‘Current use’ was defined as self-reported use of
HC at the time of study enrolment, or use within 1 year –
regardless of how many months – before the start of follow-up.
Time since first use was defined as the interval between the start of
HC use and the start of follow-up. Information about commercial
names or brands in each period of use made it possible to classify
HC as combined oral contraceptives (COCs) and progestins-only
contraceptives (POPs; pills, injectable depot medroxy-progester-
one acetate or levonorgestrel implants).
We considered the use of postmenopausal hormone therapy
(ever/never use) among the very few women who had used these at
enrolment as either combined estrogen–progestin or estrogen
only. At the start of follow-up, only women who reported a natural
menopause were considered as postmenopausal (since women
with a bilateral oophorectomy were excluded from all analyses).
Women reporting use of postmenopausal hormone therapy before
natural menopause (2902 women) and those reporting hyster-
ectomy without bilateral oophorectomy (2541 women) were
treated as having unknown menopausal status. All other women
were considered as premenopausal.
Statistical analysis
The proportional hazards assumptions were met and relative
hazards were calculated using the Cox proportional hazard model
(Cox, 1972) and SAS Software Package (version 8.2) considering
use of HC as the independent variable and epithelial ovarian
neoplasms (i.e. invasive and borderline together) and separately
invasive and borderline neoplasms as dependent variables. We
interpreted relative hazards as estimates of relative risk (RR),
which are given with 95% confidence intervals (CI). Women who
had never used HC were considered as the comparison group, if
not otherwise specified.
We kept the following covariates in the final multivariate model:
age at enrolment into the cohort (as a continuous variable), parity
(nulliparous/parous women), use of postmenopausal hormone
replacement therapy (ever/never users), menopausal status at the
start of follow-up (pre/postmenopausal and unknown menopausal
status), and country of residence (Sweden/Norway). Levels of
recreational physical activity, educational status, age at first birth,
total duration of breast-feeding, breast cancer in mother/sister, age
at menarche, and body mass index (BMI, i.e., weight in kg divided
by height in square-metres) were not included in the final
multivariate models, because they did not improve the goodness
of fit or change risk estimates meaningfully.
The characteristics of HC use such as age at first use, time since
first use, time since last use, and duration of use are closely related
and might therefore be confounded by each other. In the
multivariate analyses of age at first use, time since first use, and
time since last use, the analyses were performed both with and
without duration of use as a covariate. Ordinal ranks were assigned
to each category of duration of HC use when calculating the tests
for linear trend. The RRs for ever use of COCs and POPs were
calculated separately.
Tests for heterogeneity across subgroups of women were
performed by calculating a Wald w
2 statistic for differences
between log hazards. In this way, we tested the difference in risk
for both invasive and borderline epithelial ovarian neoplasms with
regard to never use, ever use, current use of HC, use of COCs and
POPs, and duration of use of HC, COCs, and POPs.
The responsible Data Inspection Boards and Ethical Committees
in both countries approved the study design, and all women
provided informed consent to participate in the study.
RESULTS
Characteristics of the study cohort
In the study population of 103551 women aged 30–49 years at
enrolment in 1991/92, 12% were aged 30–34, 31% were aged 35–
39, 29% were aged 40–44, and 28% were aged 45–49. During the
follow-up through year 2000, 214 cases of primary EON were
diagnosed. These were distributed as 135 cases of primary IEON
and 79 cases of BEON. The median age at diagnosis was 49 years
for IEON and 48 years for BEON; for both, the median year of
diagnosis was 1997.
We explored the parity, menopausal status, and use of
postmenopausal hormone replacement therapy as risk factors for
EON, and thus as possible confounders (Table 1). Parous women
had a decreased risk of EOC compared to nulliparous women (RR
0.6; 95% CI 0.4–0.9). We found a slight increased risk for ovarian
cancer among postmenopausal women. Use of postmenopausal
hormones (HRT) before enrolment was reported by only 3.7% of
the cohort, and was not associated with development of EON.
Risk by pattern of HC use
The risk of EON was 40% lower among ever users of HC than
among never users (after adjustment for age, parity, use of
postmenopausal hormone replacement therapy, menopausal
status, and women’s country of origin). The decreased risk of
EON was observed both among current and former users of HCs
(Table 2). There was no significant difference between the effects of
Ovarian cancer and contraceptives
M Kumle et al
1387
British Journal of Cancer (2004) 90(7), 1386–1391 & 2004 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yCOCs and POPs on risk (P¼0.98). Similarly, there was no
significant difference in risk with regard to ever use (P¼0.37) or
current use (P¼0.70) of HC.
Among the 2541 women reporting hysterectomy without
bilateral oophorectomy at enrolment, six developed EON (four
developed IEON and two developed BEON). Ever use of HC was
associated with a nonsignificant 20% decrease in risk (RR 0.8; 95%
CI 0.3–2.1 in an age-adjusted analysis) among these women.
Risk by duration and time since first and last use of HCs
Risk of EON decreased with increasing duration of HC use (P for
trend Po0.0001) (Table 3) and the reduced risk seemed to
continue beyond 10–14 years, with a RR of less than 0.1 after 15 or
more years of use. When duration of HC use was analysed as a
continuous variable, the risk was reduced by 10% per year of use
(Table 3).
Table 4 shows the RR estimates according to age at first use,
time since first use, and time since last use of HC. The multivariate
RR estimates are given both with and without adjustment for
duration of HC use. The reduced risk associated with HC use was
observed regardless of age at first use, and time since first or last
use. The effect seemed to last for more than 20 years after stopping
taking the drugs. However, when duration of HC use was taken
into account, the reduced risks of epithelial ovarian neoplasms
according to age at first use, time since first use or time since last
use were no longer statistically significant.
We were not able to carry out any meaningful detailed analysis
according to specific HC brands due to small numbers of exposed
ovarian cancer cases. None of the tests for heterogeneity across
subgroups of women with invasive and borderline tumours
(classified according to ever/current/never use of HC, use of COCs
and POPs, and duration of use of HC, COCs and POPs) were
statistically significant (data not shown).
Table 1 Characteristics of the study population at cohort enrolment, adjusted for age (The Norwegian–Swedish Women’s Lifestyle and Health Cohort
Study)
Characteristics
at cohort
enrolment
Women at risk
of ovarian
cancer Epithelial ovarian neoplasias
a IEON BEON
Number (%) Number (%)
Age-adjusted RR
(95% CI) Number (%)
Age-adjusted RR
(95% CI) Number (%)
Age-adjusted RR
(95% CI)
Parity
Never parous 12050 (11.6) 34 (15.9) 1.0 (ref) 21 (15.6) 1.0 (ref) 13 (16.5) 1.0 (ref)
Ever parous 91501 (88.4) 180 (84.1) 0.6 (0.4–0.9) 114 (84.4) 0.6 (0.4–1.0) 66 (83.5) 0.6 (0.3–1.1)
One child 14593 (14.1) 30 (14.0) 0.7 (0.4–1.1) 16 (11.8) 0.6 (0.3–1.1) 14 (17.7) 0.9 (0.4–1.8)
Two children 45240 (43.7) 91 (42.5) 0.6 (0.4–0.9) 56 (41.5) 0.6 (0.4–1.0) 35 (44.3) 0.7 (0.4–1.2)
Three or more
children
31669 (30.6) 59 (27.6) 0.5 (0.4–0.8) 42 (31.1) 0.6 (0.4–1.0) 17 (21.5) 0.4 (0.2–0.9)
Per child 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.8 (0.6–0.9)
Menopausal status at entry into the study
Premenopausal 94651 (91.4) 177 (82.7) 1.0 (ref) 111 (82.2) 1.0 (ref) 66 (83.5) 1.0 (ref)
Postmenopausal 3742 (3.6) 20 (9.4) 1.8 (1.1–2.9) 15 (11.1) 1.9 (1.1–3.3) 5 (6.3) 1.5 (0.6–3.8)
Unknown 5159 (5.0) 17 (7.9) 1.2 (0.7–2.0) 9 (6.7) 0.9 (0.5–1.9) 8 (10.2) 1.8 (0.9–3.9)
Ever used HRT
b
No 99757 (96.3) 197 (92.1) 1.0 (ref) 125 (92.6) 1.0 (ref) 72 (91.1) 1.0 (ref)
Yes 3795 (3.7) 17 (7.9) 1.5 (0.9–2.5) 10 (7.4) 1.3 (0.7–2.4) 7 (8.9) 2.0 (0.9–4.5)
aInvasive epithelial ovarian neoplasias (IEON) and borderline epithelial ovarian neoplasias (BEON) together.
bPostmenopausal hormone replacement therapy (oestrogens only,
or oestrogens added to progestins).
Table 2 Relative risks (RR) with 95% confidence intervals (CI) for ovarian epithelial neoplasias according to pattern of hormonal contraceptive use at
cohort enrolment (The Norwegian–Swedish Women’s Lifestyle and Health Cohort Study)
Use of hormonal
contraceptives at
cohort enrolment
Epithelial ovarian neoplasias
a IEON BEON
Women at risk of
ovarian cancer Number
RR (95% CI)
Multivariate
b Number
RR (95% CI)
Multivariate
b Number
RR (95% CI)
Multivariate
b
Never users 28019 93 1.0 (Ref.) 63 1.0 (Ref.) 30 1.0 (Ref.)
Ever users 75533 121 0.6 (0.5–0.8) 72 0.6 (0.4–0.8) 49 0.7 (0.5–1.2)
POPs
c 4438 6 0.5 (0.2–1.2) 2 0.3 (0.1–1.1) 4 1.0 (0.4–2.9)
COCs
d 42616 58 0.5 (0.4–0.7) 36 0.5 (0.3–0.8) 22 0.6 (0.3–1.0)
Both COCs and POPs
or unknown brand
28479 57 0.7 (0.5–1.0) 34 0.7 (0.4–1.0) 23 0.9 (0.5–1.5)
Current users 9805 9 0.5 (0.2–0.9) 5 0.4 (0.2–1.0) 4 0.5 (0.2–1.6)
Former users 65728 112 0.6 (0.5–0.8) 67 0.6 (0.4–0.8) 45 0.7 (0.5–1.2)
aInvasive epithelial ovarian neoplasias (IEON) and borderline epithelial ovarian neoplasias (BEON) together.
bAdjusted for baseline information about: age (continuous variable in
completed years), parity (nulliparous vs parous), use of postmenopausal hormone therapy (ever vs never), menopausal status (pre-, post-menopausal or unknown menopausal
status at the start of follow-up) and country (Sweden/Norway).
cPOPs¼progestins-only preparations.
dCOCs¼Combined oral contraceptives.
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In our study, we confirm a strong inverse risk association between
use of HC and epithelial ovarian neoplasms. Women who used HC
for many years were at particularly lower risk as compared to
women who were never users. We found no evidence of differential
effect of HC use on the development of invasive or borderline
tumours. Nor was the impact of use of combined estrogen–
progestin contraceptives and progestins-only contraceptives dif-
ferent from each other with regard to cancer risk.
The strength of this study is the prospective design, the large
size, and the complete follow-up based on linkage to national
registers (Lunde et al, 1980). Since cancer registration is
compulsory in both countries, the assessment of cases is virtually
complete. A limitation of this study is the lacked of systematic
validation of the self-administrated questionnaire. Studies of the
reproducibility and validity of questions about HC use have been
carried out by others (Coulter et al, 1986; Nischan et al, 1993;
Hunter et al, 1997). Although accurate reporting of HC use is
important, HC use in both case–control and cohort studies is
obtained retrospectively and distant use might be poorly recalled.
Since the information about HC was obtained at enrolment,
changes in exposure status are not accounted for. Only 9% of the
women were current users of HC at enrolment. Particularly the
youngest women in the cohort might have changed the brand of
HC used, ceased or started with HC during the follow-up period.
Similarly, women aged 40 years or more at enrolment, who were
current HC users, had most probably ceased their use during the
follow-up. Such changes in the patterns of use during follow-up
may have caused misclassification of exposure. Many important
reproductive factors for ovarian cancer are likely to vary in ways
that are related to each other (e.g. women who have had children
Table 3 Relative risks (RR) with 95% confidence intervals (CI) for epithelial ovarian neoplasias according to duration of hormonal contraceptive use at
cohort enrolment (The Norwegian–Swedish Women’s Lifestyle and Health Cohort Study)
Use of hormonal
contraceptives at
cohort enrolment
Epithelial ovarian neoplasias
a IEON BEON
Women at risk of
ovarian cancer Number
RR (95% CI)
Multivariate
b Number
RR (95% CI)
Multivariate
b Number
RR (95% CI)
Multivariate
b
Never users 28019 93 1.0 (Ref.) 63 1.0 (Ref.) 30 1.0 (Ref.)
Duration of HC use
o1 year 8493 21 0.9 (0.5–1.4) 19 1.2 (0.7–2.0) 2 0.2 (0.1–1.0)
1–4 years 23688 35 0.5 (0.4–0.8) 21 0.5 (0.3–0.8) 14 0.6 (0.3–1.2)
5–9 years 20719 33 0.6 (0.4–0.9) 19 0.6 (0.3–0.9) 14 0.7 (0.4–1.4)
10–14 years 9795 13 0.5 (0.3–1.0) 5 0.3 (0.1–0.8) 8 0.9 (0.4–2.0)
15+ years 4348 1 0.1 (0.01–0.6) 1 0.1 (0.02–0.8) — —
P for trend Po0.0001 Po0.0001 P¼0.2
Per year of use 0.92 (0.88–0.96) 0.89 (0.84–0.94) 0.96 (0.91–1.0)
aInvasive epithelial ovarian neoplasias (IEON) and borderline epithelial ovarian neoplasias (BEON) together.
bAdjusted for baseline information about: age (continuous variable in
completed years), parity (nulliparous vs parous), use of postmenopausal hormone therapy (ever vs never), menopausal status (pre-, post-menopausal or unknown menopausal
status at the start of follow-up) and country (Sweden/Norway).
Table 4 Relative risks (RR) with 95% confidence intervals (CI) for epithelial ovarian neoplasias according to information about age at first use, time since
first use and time since last use of hormonal contraceptives at cohort enrolment (The Norwegian–Swedish Women’s Lifestyle and Health Cohort Study)
Use of hormonal
contraceptives at
cohort enrolment
Epithelial ovarian neoplasia
a IEON BEON
Women at risk of
ovarian cancer Number
RR (95% CI)
Multivariate
b
RR (95% CI)
Multivariate, adjusted
for duration of use Number
RR (95% CI)
Multivariate
b Number
RR (95% CI)
Multivariate
b
Never users 28019 93 1.0 (Ref.) 1.0 (Ref.) 63 1.0 (Ref.) 30 1.0 (Ref.)
Age at first use
o20 years 31262 32 0.5 (0.3–0.8) 0.6 (0.3–1.0) 21 0.5 (0.3–1.0) 11 0.4 (0.2–0.9)
20–24 years 29014 49 0.6 (0.4–0.8) 0.7 (0.5–1.1) 25 0.4 (0.3–0.7) 24 0.8 (0.5–1.4)
25+ years 14576 38 0.8 (0.5–1.1) 1.0 (0.6–1.5) 25 0.7 (0.5–1.1) 13 0.8 (0.4–1.4)
Time since first use
0–19 years 40402 55 0.7 (0.5–1.0) 0.9 (0.6–1.4) 33 0.7 (0.4–1.1) 22 0.7 (0.4–1.2)
20+ years 34450 64 0.5 (0.4–0.8) 0.7 (0.5–1.1) 38 0.5 (0.3–0.7) 26 0.7 (0.4–1.3)
Time since last use
0–9 years 26799 27 0.5 (0.3–0.7) 0.9 (0.5–1.7) 17 0.5 (0.3–0.8) 10 0.4 (0.2–0.9)
10–14 years 13928 25 0.7 (0.4–1.1) 1.1 (0.6–1.9) 11 0.5 (0.2–0.9) 14 1.1 (0.6–2.1)
15–19 years 15205 26 0.6 (0.45–0.9) 0.8 (0.5–1.3) 17 0.6 (0.3–1.0) 9 0.6 (0.3–1.3)
20+ years 11085 22 0.5 (0.3–0.9) 0.6 (0.4–1.0) 17 0.6 (0.3–1.0) 5 0.4 (0.2–1.0)
aInvasive epithelial ovarian neoplasias (IEON) and borderline epithelial ovarian neoplasias (BEON) together.
bAdjusted for baseline information about: age (continuous variable in
completed years), parity (nulliparous vs parous), use of postmenopausal hormone therapy (ever vs never), menopausal status (pre-, post- or unknown menopausal status at the
start of follow-up) and country (Sweden/Norway).
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ymay then start contraceptives, women who stop contraceptives
may then get pregnant, etc.), and may be misclassified over time in
our study. The impact of such possible misclassification will only
be known once we have updated information on the entire cohort,
which is ongoing at the moment. However, due to their ages, we
believe that most participating women had probably ended their
reproductive life at enrolment, so that changes in parity during
follow-up probably have a very modest impact as a confounder on
the overall association with HC. It is expected that at least a few
women would have undergone hysterectomy and/or tubal ligation
during follow-up, but they should not change substantially the
association between use of HC and ovarian cancer risk.
Our study indicates that the positive effect of HC on ovarian
neoplasms is associated with the duration of use, the effect rising
with each additional year of use. However, the finding of an
important reduced risk in women with very long duration (15 or
more years) was based on only one case. After including the
duration in the analytical models, no independent effect was
observed for age at first use, or for time since the first or last use.
Thus, duration, rather than time of use, seems to be the most
important in determining a decreasing ovarian cancer risk.
Few analyses of prospective studies on HC and ovarian
neoplasms are available and three out of the four studies were
based on small numbers (Ramcharan et al, 1980; Beral et al, 1988;
Vessey and Painter, 1995). Only the most recent, the Nurses’
Health Study (Hankinson et al, 1995), did not confirm a protective
effect (including both invasive and borderline cases). In the
analysis of the Nurses’ Health Study, based on 260 cases, the
exposure was restricted to shorter durations of use than in other
studies. The nurses were aged 30–55 years in 1976 at enrolment,
while the women in our study were 30–49 years in 1991. Thus, the
opportunity to be ever exposed to HC differed greatly.
In our study, there was no statistically significant difference
between the effect of use of HC on risk of invasive or borderline
neoplasms, in agreement with most previous studies (Riman,
2003).
Epidemiological evidence from case–control studies on use of
COCs and ovarian cancer risk is well defined and consistent (IARC
Working Group, 1999): at least 20 out of 21 studies published
between 1980 and 1997 found RRs below unity. Little information
is available on progestins-only contraceptives and risk, but none of
the published studies showed any alteration in risk according to
the type of hormonal content (IARC Working Group, 1999).
Ovarian cancer incidence rates have remained constant or have
declined in Norway and Sweden over the last two decades (Adami
et al, 1990; Bjorge et al, 1997). At the same time, both the incidence
and the duration of HC use in the Nordic countries have been
increasing. Since the incidence of ovarian cancer is already
appreciable in middle age, and the prognostic outlook is gloomy,
a reduction of risk attributable to HC use would be important in
any risk–benefit evaluation (Parazzini et al, 2000). Further
research would be necessary to establish whether there has been
a direct link between rising HC use and declining ovarian cancer
incidence in Norway and Sweden.
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